Pharmacokinetics of mycophenolic acid in renal insufficiency

Herwig Ulf Meier-Kriesche, Leslie M. Shaw, Magdalena Korecka, Bruce Kaplan

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Mycophenolate mofetil (MMF) is now widely used in solid organ transplantation. MMF is rapidly converted to its active form, mycophenolic acid (MPA), upon reaching the systemic circulation. MPA is metabolized to its glucuronide metabolite, mycophenolic acid glucuronide (MPAG), by glucoronyl transferases in the liver and possibly elsewhere. MPAG is then excreted by the kidney. MPA is extensively and avidly bound to serum albumin. Previous studies have demonstrated that it is only the free (non-protein-bound) fraction of MPA that is available to exert its action. In vivo and in vitro studies demonstrate that renal insufficiency decreases the protein binding of MPA and increases free MPA concentrations. This decrease in protein binding seems to be caused both by the uremic state itself and by competition with the retained metabolite MPAG. The disposition of MPA in patients with severe renal impairment may be significantly affected by this change in protein binding.

Original languageEnglish (US)
Pages (from-to)27-30
Number of pages4
JournalTherapeutic Drug Monitoring
Volume22
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Mycophenolic Acid
Pharmacokinetics
Renal Insufficiency
Protein Binding
Metabolites
Transplantation (surgical)
Kidney
Glucuronides
Organ Transplantation
Transferases
Serum Albumin
Liver

Keywords

  • Mycophenolate mofetil
  • Pharmacokinetics

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Pharmacokinetics of mycophenolic acid in renal insufficiency. / Meier-Kriesche, Herwig Ulf; Shaw, Leslie M.; Korecka, Magdalena; Kaplan, Bruce.

In: Therapeutic Drug Monitoring, Vol. 22, No. 1, 2000, p. 27-30.

Research output: Contribution to journalArticle

Meier-Kriesche, HU, Shaw, LM, Korecka, M & Kaplan, B 2000, 'Pharmacokinetics of mycophenolic acid in renal insufficiency', Therapeutic Drug Monitoring, vol. 22, no. 1, pp. 27-30. https://doi.org/10.1097/00007691-200002000-00005
Meier-Kriesche, Herwig Ulf ; Shaw, Leslie M. ; Korecka, Magdalena ; Kaplan, Bruce. / Pharmacokinetics of mycophenolic acid in renal insufficiency. In: Therapeutic Drug Monitoring. 2000 ; Vol. 22, No. 1. pp. 27-30.
@article{2a92523522c04c98810aa98fbb7ac70e,
title = "Pharmacokinetics of mycophenolic acid in renal insufficiency",
abstract = "Mycophenolate mofetil (MMF) is now widely used in solid organ transplantation. MMF is rapidly converted to its active form, mycophenolic acid (MPA), upon reaching the systemic circulation. MPA is metabolized to its glucuronide metabolite, mycophenolic acid glucuronide (MPAG), by glucoronyl transferases in the liver and possibly elsewhere. MPAG is then excreted by the kidney. MPA is extensively and avidly bound to serum albumin. Previous studies have demonstrated that it is only the free (non-protein-bound) fraction of MPA that is available to exert its action. In vivo and in vitro studies demonstrate that renal insufficiency decreases the protein binding of MPA and increases free MPA concentrations. This decrease in protein binding seems to be caused both by the uremic state itself and by competition with the retained metabolite MPAG. The disposition of MPA in patients with severe renal impairment may be significantly affected by this change in protein binding.",
keywords = "Mycophenolate mofetil, Pharmacokinetics",
author = "Meier-Kriesche, {Herwig Ulf} and Shaw, {Leslie M.} and Magdalena Korecka and Bruce Kaplan",
year = "2000",
doi = "10.1097/00007691-200002000-00005",
language = "English (US)",
volume = "22",
pages = "27--30",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of mycophenolic acid in renal insufficiency

AU - Meier-Kriesche, Herwig Ulf

AU - Shaw, Leslie M.

AU - Korecka, Magdalena

AU - Kaplan, Bruce

PY - 2000

Y1 - 2000

N2 - Mycophenolate mofetil (MMF) is now widely used in solid organ transplantation. MMF is rapidly converted to its active form, mycophenolic acid (MPA), upon reaching the systemic circulation. MPA is metabolized to its glucuronide metabolite, mycophenolic acid glucuronide (MPAG), by glucoronyl transferases in the liver and possibly elsewhere. MPAG is then excreted by the kidney. MPA is extensively and avidly bound to serum albumin. Previous studies have demonstrated that it is only the free (non-protein-bound) fraction of MPA that is available to exert its action. In vivo and in vitro studies demonstrate that renal insufficiency decreases the protein binding of MPA and increases free MPA concentrations. This decrease in protein binding seems to be caused both by the uremic state itself and by competition with the retained metabolite MPAG. The disposition of MPA in patients with severe renal impairment may be significantly affected by this change in protein binding.

AB - Mycophenolate mofetil (MMF) is now widely used in solid organ transplantation. MMF is rapidly converted to its active form, mycophenolic acid (MPA), upon reaching the systemic circulation. MPA is metabolized to its glucuronide metabolite, mycophenolic acid glucuronide (MPAG), by glucoronyl transferases in the liver and possibly elsewhere. MPAG is then excreted by the kidney. MPA is extensively and avidly bound to serum albumin. Previous studies have demonstrated that it is only the free (non-protein-bound) fraction of MPA that is available to exert its action. In vivo and in vitro studies demonstrate that renal insufficiency decreases the protein binding of MPA and increases free MPA concentrations. This decrease in protein binding seems to be caused both by the uremic state itself and by competition with the retained metabolite MPAG. The disposition of MPA in patients with severe renal impairment may be significantly affected by this change in protein binding.

KW - Mycophenolate mofetil

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0033983513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033983513&partnerID=8YFLogxK

U2 - 10.1097/00007691-200002000-00005

DO - 10.1097/00007691-200002000-00005

M3 - Article

C2 - 10688253

AN - SCOPUS:0033983513

VL - 22

SP - 27

EP - 30

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -